Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

125 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer.
Lahn M, McClelland P, Ballard D, Mintze K, Thornton D, Sandusky G. Lahn M, et al. Histopathology. 2006 Oct;49(4):429-31. doi: 10.1111/j.1365-2559.2006.02461.x. Histopathology. 2006. PMID: 16978209 No abstract available.
Protein kinase C-beta II (PKC-beta II) expression in patients with colorectal cancer.
Spindler KL, Lindebjerg J, Lahn M, Kjaer-Frifeldt S, Jakobsen A. Spindler KL, et al. Among authors: lahn m. Int J Colorectal Dis. 2009 Jun;24(6):641-5. doi: 10.1007/s00384-009-0680-8. Epub 2009 Mar 10. Int J Colorectal Dis. 2009. PMID: 19277684
Expression levels of protein kinase C-alpha in non-small-cell lung cancer.
Lahn M, Su C, Li S, Chedid M, Hanna KR, Graff JR, Sandusky GE, Ma D, Niyikiza C, Sundell KL, John WJ, Giordano TJ, Beer DG, Paterson BM, Su EW, Bumol TF. Lahn M, et al. Clin Lung Cancer. 2004 Nov;6(3):184-9. doi: 10.3816/clc.2004.n.032. Clin Lung Cancer. 2004. PMID: 15555220
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK, Lahn M, Gandara DR. Paz-Ares L, et al. Among authors: lahn m. J Clin Oncol. 2006 Mar 20;24(9):1428-34. doi: 10.1200/JCO.2005.04.3299. J Clin Oncol. 2006. PMID: 16549837 Clinical Trial.
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G. Oh Y, et al. Among authors: lahn m. J Clin Oncol. 2008 Mar 1;26(7):1135-41. doi: 10.1200/JCO.2007.14.3685. J Clin Oncol. 2008. PMID: 18309949 Clinical Trial.
Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer.
Vansteenkiste J, Canon JL, Riska H, Pirker R, Peterson P, John W, Mali P, Lahn M. Vansteenkiste J, et al. Among authors: lahn m. Invest New Drugs. 2005 Jun;23(3):263-9. doi: 10.1007/s10637-005-6736-x. Invest New Drugs. 2005. PMID: 15868384 Clinical Trial.
Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
Roychowdhury D, Lahn M. Roychowdhury D, et al. Among authors: lahn m. Semin Oncol. 2003 Apr;30(2 Suppl 3):30-3. doi: 10.1053/sonc.2003.37273. Semin Oncol. 2003. PMID: 12722024 Review.
Targeting protein kinase C-alpha (PKC-alpha) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen.
Lahn M, Sundell K, Moore S. Lahn M, et al. Ann N Y Acad Sci. 2003 Dec;1002:263-70. doi: 10.1196/annals.1281.029. Ann N Y Acad Sci. 2003. PMID: 14751841 Review.
The role of protein kinase C-alpha (PKC-alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen.
Hanauske AR, Sundell K, Lahn M. Hanauske AR, et al. Among authors: lahn m. Curr Pharm Des. 2004;10(16):1923-36. doi: 10.2174/1381612043384376. Curr Pharm Des. 2004. PMID: 15180529 Review.
Protein kinase C alpha expression in breast and ovarian cancer.
Lahn M, Köhler G, Sundell K, Su C, Li S, Paterson BM, Bumol TF. Lahn M, et al. Oncology. 2004;67(1):1-10. doi: 10.1159/000080279. Oncology. 2004. PMID: 15459489 Review.
125 results
Jump to page